Pharma news
Pharma
The Unified Patent Court Agreement has not quite reached a safe harbour yet, but it is close. 7 December 2016
Americas
The complications surrounding second medical use patents risks the pharmaceutical industry again becoming a “big, bad wolf”. 7 December 2016
Pharma
Intellectual property is the lifeblood of the life sciences industry and innovation is key, according to Nicola Dagg, head of Allen & Overy’s IP litigation practice in London. 7 December 2016
Americas
Astellas Pharma, Medivation and the regents of the University of California have collectively sued Actavis for alleged patent infringement over Xtandi, a treatment for prostate cancer. 6 December 2016
Americas
Anyone seeking a deal with a life sciences company must understand the value and potential risks of its IP, as Karen Mangasarian and Ryan Murphey of Ropes & Gray explain. 6 December 2016
Americas
Forest Laboratories, Allergan and Ironwood Pharmaceuticals have filed a complaint against Teva, Mylan, Sandoz and Aurobindo for alleged patent infringement. 2 December 2016
Americas
Merck has filed a complaint against Strides Pharma for alleged patent infringement over Sustiva, an antiviral medication that prevents HIV from multiplying in the human body. 1 December 2016
Americas
A US district court has dismissed a patent infringement lawsuit between US-based biotechnology company Genzyme and Mylan Pharmaceuticals after the companies agreed to settle. 30 November 2016
Pharma
UK life sciences organisations are still uncertain about the implications of Britain’s departure from the EU, despite welcoming the announcement that the UK will ratify the Unified Patent Court Agreement. 30 November 2016
Africa
Mylan has entered into a sub-licensing agreement with the Medicines Patent Pool, a UN-backed public health organisation, to expand access to chronic hepatitis C medicines in developing countries. 29 November 2016